NASDAQ: NKTR - Nektar Therapeutics

Yield per half year: -7.53%
Sector: Healthcare

Download the report: word Word , pdf PDF

1. Summary

Advantages

  • Positive review The stock's return over the last year (-76.27%) is higher than the sector average (-99.21%).
  • Positive review Current debt level 18.51% is below 100% and has decreased over 5 years from 64.65%.

Disadvantages

  • Negative review Price (0.712 $) is higher than fair price (0.6361 $)
  • Negative review Dividends (0%) are below the sector average (1.8652%).
  • Negative review The company's current efficiency (ROE=-70.39%) is lower than the sector average (ROE=12.27%)

2. Share price and performance

2.1. Share price

2.2. News

2.3. Market efficiency

Nektar Therapeutics Healthcare Index
7 days 4.7% -98.2% -1.4%
90 days 45.3% -99.3% -0.3%
1 year -76.3% -99.2% 47.9%

Positive review NKTR vs Sector: Nektar Therapeutics has outperformed the "Healthcare" sector by 22.94% over the past year.

Negative review NKTR vs Market: Nektar Therapeutics has significantly underperformed the market by -124.15% over the past year.

Positive review Stable price: NKTR is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: NKTR with weekly volatility of -1.4667% over the past year.

3. Summary of the report

3.1. General

P/E: 0
P/S: 4.37

3.2. Revenue

EPS -1.9675
ROE -70.39%
ROA -40.29%
ROIC -49.32%
Ebitda margin -134.25%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Negative review company.analysis.fundamental.minus11_title: The current price (0.712 $) is higher than the fair price (0.6361 $).

Negative review Price is higher than fair: The current price (0.712 $) is 10.7% higher than the fair price.

4.2. P/E

Positive review P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (50.18).

Positive review P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (86.87).

4.2.1 P/E Similar companies

4.3. P/BV

Negative review P/BV vs Sector: The company's P/BV (1.0974) is higher than that of the sector as a whole (0.0365).

Positive review P/BV vs Market: The company's P/BV (1.0974) is lower than that of the market as a whole (4.66).

4.3.1 P/BV Similar companies

4.4. P/S

Positive review P/S vs Sector: The company's P/S indicator (4.37) is lower than that of the sector as a whole (5.26).

Positive review P/S vs Market: The company's P/S indicator (4.37) is lower than that of the market as a whole (10.15).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

Positive review EV/Ebitda vs Sector: The company's EV/Ebitda (-2.02) is lower than that of the sector as a whole (16.14).

Positive review EV/Ebitda vs Market: The company's EV/Ebitda (-2.02) is lower than that of the market as a whole (26.53).


5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Ebitda

Negative review Yield Trend: Negative and has fallen by -6.67% over the last 5 years.

Negative review Earnings Slowdown: The last year's return (-29.19%) is below the 5-year average return (-6.67%).

Negative review Profitability vs Sector: The return for the last year (-29.19%) is lower than the return for the sector (137.38%).

5.4. ROE

Negative review ROE vs Sector: The company's ROE (-70.39%) is lower than that of the sector as a whole (12.27%).

Negative review ROE vs Market: The company's ROE (-70.39%) is lower than that of the market as a whole (8.7%).

5.5. ROA

Negative review ROA vs Sector: The company's ROA (-40.29%) is lower than that of the sector as a whole (7.3%).

Negative review ROA vs Market: The company's ROA (-40.29%) is lower than that of the market as a whole (6.02%).

5.6. ROIC

Negative review ROIC vs Sector: The company's ROIC (-49.32%) is lower than that of the sector as a whole (13.31%).

Negative review ROIC vs Market: The company's ROIC (-49.32%) is lower than that of the market as a whole (10.68%).

6. Finance

6.1. Assets and debt

Positive review Debt level: (18.51%) is quite low in relation to assets.

Positive review Debt reduction: over 5 years, the debt has decreased from 64.65% to 18.51%.

Negative review Excess of debt: The debt is not covered by net income, percentage -44.77%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Negative review Low yield: The dividend yield of the company 0% is below the average for the sector '1.8652%.

7.2. Stability and increase in payments

Negative review Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Negative review Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Negative review Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Positive review Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

Transaction date Insider Type Price Volume Quantity
18.09.2023 Ajer Jeffrey Robert
Director
Sale 0.69 3 008 4359
18.09.2023 Curet Myriam
Director
Sale 0.69 3 008 4359
16.02.2023 ROBIN HOWARD W
President & CEO
Sale 3 58 905 19635
16.02.2023 Thomsen Jillian B.
Chief Financial Officer
Sale 3 30 801 10267
16.02.2023 Wilson Mark Andrew
Chief Legal Officer
Sale 3 24 825 8275